Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.
Britt Erickson, MD
Advertisement
Articles by Britt Erickson, MD
Britt Erickson, MD, discusses the benefit of PARP inhibitor maintenance therapy in patients with BRCA-mutated ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5